awmsg logo



everolimus (Certican®)


Reference No. 1287

Publication date:
20/05/2015


Appraisal information

everolimus (Certican®) 1 mg tablet
everolimus (Certican®) 0.25 mg tablet
everolimus (Certican®) 0.50 mg tablet
everolimus (Certican®) 0.75 mg tablet


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Superseded
Advice No: Not available
Ratification by Welsh Government: 15/05/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA348) NICE GUIDANCE ISSUED JULY 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) In the absence of a submission from the holder of the marketing authorisation, everolimus (Certican®) cannot be endorsed for use within NHS Wales for the prophylaxis of organ rejection in patients receiving a hepatic transplant.
Statement of Advice (SOA)
Download